Pharmaceutical ethers
AssigneeBurroughts Wellcome Co.
InventorGeoffrey Kneen
Life of this patent
Estimating the term…
Abstract
This invention is directed to novel ether compounds of formula (I) ##STR1## which are of value in medicine in the palliation of haemoglobinopathies, in particular sickle-cell anaemia, and also in the palliation of pulmonary dysfunction, protection from the effects of hypoxia and the radio-sensitization of tumors. The invention is also directed to methods for the preparation of the ether compounds, to pharmaceutical formulations containing them, the preparation of such formulations and the use of the compounds in human medicine. Also provided by the invention are intermediates of value in the preparation of the ether compounds, by the methods described, and the preparation of the intermediates.
Claims58
A compound of formula (I) ##STR17## wherein Q.sup.1 is selected from ##STR18## where Q.sup.2 and Q.sup.3 are independently selected from hydrogen and alkyl of 1 to 4 carbon atoms, and X is selected from cyano, carboxyl and 5-tetrazolyl;
- salts thereof and, when X is carboxyl, esters and amides thereof,
A compound of formula (I) ##STR19## wherein
- Q.sup.1 is --(CH.sub.2).sub.2 --CH.sub.2 --X
- where X is carboxyl or 5-tetrazolyl;
- salts thereof and, when X is carboxyl, esters and amides thereof.
5-(2-Formyl-3-hydroxyphenoxy)-2-methylpentanoic acid and salts thereof.
5-(2-Formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid and salts thereof.
3-(2-Formyl-3-hydroxyphenoxy)methylbenzoic acid and salts thereof.
5-(2-Formyl-3-hydroxyphenoxy)pentanoic acid or a salt thereof.
5-(2-Formyl-3-hydroxyphenoxy)pentanoic acid.
A pharmaceutical formulation comprising a compound of formula (I) ##STR24## wherein Q.sup.1 is selected from ##STR25## where Q.sup.2 and Q.sup.3 are independently selected from hydrogen and alkyl of 1 to 4 carbon atoms, and X is selected from cyano, carboxyl and 5-tetrazolyl, a pharmacologically acceptable salt thereof or, when X is carboxyl, an ester or an amide thereof, together with an acceptable carrier therefor.
A pharmaceutical formulation comprising a compound of formula (I) ##STR26## wherein
- Q.sup.1 is --(CH.sub.2).sub.2 --CH.sub.2 --X
- where X is carboxyl or 5-tetrazolyl, a pharmacologically acceptable salt thereof or, when X is carboxyl, an ester or an amide thereof, together with an acceptable carrier therefor.
A pharmaceutical formulation comprising 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid, or a pharmacologically acceptable salt thereof, together with an acceptable carrier therefor.
A pharmaceutical formulation comprising 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid together with an acceptable carrier therefor.
Ethers of the formula ##STR27## wherein Q.sup.1 is selected from ##STR28## where Q.sup.2 and Q.sup.3 are independently selected from hydrogen and alkyl of 1 to 4 carbon atoms and
- X is selected from cyano, carboxyl and 5-tetrazolyl;
- and
- Z.sup.2 is alkyl;
- salts of said compounds and, when X is carboxyl, esters and amides thereof.
Dependencies are inferred from the claim text.